Dynamic Proteomic Changes in Tumor and Immune Organs Reveal Systemic Immune Response to Tumor Development

Zhike Li1, Shuwen Liu1, Zhouyong Gao2

  • 1State Key Laboratory of Medical Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Beijing Institute of Lifeomics, Beijing, China.

Insights

This study reveals how tumors interact with immune organs over time. Targeting MEK and DDR2 simultaneously shows promise for reducing tumor growth in mouse models.

Area of Science:

  • Oncology
  • Immunology
  • Proteomics

Background:

  • Tumor progression involves complex interactions between tumor cells, stromal cells, and immune cells.
  • The host's macroenvironment, including immune organs, response to tumorigenesis is poorly understood.
  • Temporal proteomic analysis provides insights into these dynamic interactions.

Purpose of the Study:

  • To conduct a temporal proteomic analysis of a subcutaneous tumor and associated immune organs (lymph node, mesenteric lymph node, spleen) in a mouse model.
  • To understand the host's immune response dynamics during tumor development.
  • To identify potential therapeutic targets by analyzing proteomic changes in both tumors and immune organs.

Main Methods:

  • Syngeneic mouse model of forestomach cancer.
  • Temporal proteomic analysis of tumor and immune organs (LN, MLN, spleen) at multiple time points (Days 0, 3, 7, 10, 14, 21).
  • Bioinformatics analysis to identify biological processes and proteomic changes.

Main Results:

  • Identified distinct phases of tumor development: acute immune response, host immune attack, adaptive immune activation, and extracellular matrix buildup.
  • Proteomic changes in lymph node and spleen mirrored tumor immune response dynamics (acute defense, adaptive response, immune evasion).
  • Mesenteric lymph node showed a delayed but sustained immune activation, suggesting a distal response.

Conclusions:

  • Combined analysis of tumors and immune organs reveals crucial interactions during tumorigenesis.
  • Identified MEK and DDR2 as potential therapeutic targets.
  • Dual inhibition of MEK and DDR2 significantly reduced tumor growth in a proof-of-concept experiment, highlighting their therapeutic potential.

Related Concept Videos

Proteomics01:33

Proteomics

A proteome is the entire set of proteins that a cell type produces. We can study proteomes using the knowledge of genomes because genes code for mRNAs, and the mRNAs encode proteins. Although mRNA analysis is a step in the right direction, not all mRNAs are translated into proteins.
Proteomics is the study of proteomes' function. It involves the large-scale systematic study of the proteome to denote the protein complement expressed by a genome. Scientist Mark Wilkins coined the term...
7.3K
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K